Last reviewed · How we verify
generic warfarin #1
Generic warfarin #1, developed by the Federal University of São Paulo, is a marketed anticoagulant with a well-established presence in the therapeutic landscape. The key composition patent expires in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the lack of revenue data and key trial results, which may limit strategic planning and competitive analysis.
At a glance
| Generic name | generic warfarin #1 |
|---|---|
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Drug Interaction Study of Danicopan (PHASE1)
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- generic warfarin #1 CI brief — competitive landscape report
- generic warfarin #1 updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI